Background and Aims: Pancreatic cancer risk is increased in Lynch syndrome (LS) patients with mismatch repair gene defects predisposing to colonic and extracolonic cancers with microsatellite instability (MSI). However, the frequency of MSI pancreatic cancers has never been ascertained in consecutive, unselected clinical series, and their contribution to the sporadic and inherited burden of pancreatic cancer remains to be established. Aims of the study were to determine the prevalence of MSI in surgically resected pancreatic cancers in a multicentric, retrospective study, and to assess the occurrence of pancreatic cancer in LS. Methods: MS-status was screened by a panel of 5 mononucleotide repeats (Bat26, Bat25, NR-21, NR-24 and NR-27) in 3...
The MLH1 c.2252_2253delAA mutation was found in 11 unrelated families from a restricted area southw...
Purpose: Replication error is an important mechanism in carcinogenesis. The microsatellite instabili...
ObjectiveImmune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable...
Pancreatic cancer risk is increased in Lynch syndrome (LS) patients with mismatch repair gene defect...
Pancreatic cancer risk is increased in Lynch syndrome (LS) patients with mismatch repair gene defect...
Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus res...
L’adénocarcinome canalaire du pancréas (ACP) est un problème majeur de santé publique. L’ACP se déve...
Lynch syndrome is an inherited cancer syndrome caused by germline mutations in mismatch repair (MMR)...
Microsatellite instability (MSI) caused by mismatch repair deficiency (dMMR) is detected in a small ...
Objective: Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dM...
Background: Pancreatic Ductal AdenoCarcinoma (PDAC) may present MicroSatellite Instability (MSI), ph...
Objectives: Molecular alterations inaboit 1%of Pancreatic Ductal AdenoCarcinoma(PDAC) includes Micro...
Objective Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMM...
Although colorectal cancer (CRC) is the most common cancer type in Lynch syndrome (LS) families, pat...
Background: Molecular alterations described in Pancreatic Ductal AdenoCarcinoma (PDAC) include Micro...
The MLH1 c.2252_2253delAA mutation was found in 11 unrelated families from a restricted area southw...
Purpose: Replication error is an important mechanism in carcinogenesis. The microsatellite instabili...
ObjectiveImmune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable...
Pancreatic cancer risk is increased in Lynch syndrome (LS) patients with mismatch repair gene defect...
Pancreatic cancer risk is increased in Lynch syndrome (LS) patients with mismatch repair gene defect...
Pancreatic cancer is one of the most aggressive malignancies with limited treatment options thus res...
L’adénocarcinome canalaire du pancréas (ACP) est un problème majeur de santé publique. L’ACP se déve...
Lynch syndrome is an inherited cancer syndrome caused by germline mutations in mismatch repair (MMR)...
Microsatellite instability (MSI) caused by mismatch repair deficiency (dMMR) is detected in a small ...
Objective: Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dM...
Background: Pancreatic Ductal AdenoCarcinoma (PDAC) may present MicroSatellite Instability (MSI), ph...
Objectives: Molecular alterations inaboit 1%of Pancreatic Ductal AdenoCarcinoma(PDAC) includes Micro...
Objective Recently, tumours with microsatellite instability (MSI)/defective DNA mismatch repair (dMM...
Although colorectal cancer (CRC) is the most common cancer type in Lynch syndrome (LS) families, pat...
Background: Molecular alterations described in Pancreatic Ductal AdenoCarcinoma (PDAC) include Micro...
The MLH1 c.2252_2253delAA mutation was found in 11 unrelated families from a restricted area southw...
Purpose: Replication error is an important mechanism in carcinogenesis. The microsatellite instabili...
ObjectiveImmune therapy with the PD1 inhibitor pembrolizumab has been approved to treat unresectable...